CIK 0001130166 · Non-accelerated filer<br>Smaller reporting company
Bio Green Med Solution, Inc.
Sign in to watch- Tickers
- BGMS BGMSP
- Exchange
- Nasdaq, OTC
- Industry
- Wholesale-Durable Goods, NEC
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 911766850
- Phone
- 908-517-7330
- Business address
- 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS, NJ, 07922
- Former names
- Cyclacel Pharmaceuticals, Inc., XCYTE THERAPIES INC
Securities
- BGMS Common Stock Nasdaq
- BGMSP Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 99 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-07-30 | Lazar David E. 10% owner | Sale | −6,750 | $12.36 | $83K | 155,838 |
| 2025-02-26 | NATAN DAVID Director | Grant or award · Non-Qualified Stock Option (Right to Buy) | +700,000 | 700,000 | ||
| 2025-02-26 | Lazar David E. Interim CEO | Option exercise | +2,650,000 | 2,650,000 | ||
| 2025-02-26 | Lazar David E. Interim CEO | Option exercise | +191,978,820 | 194,628,820 | ||
| 2025-02-26 | Lazar David E. Interim CEO | Sale | −194,628,820 | $0.03 | $5.5M | 0 |
| 2025-02-26 | Lazar David E. Interim CEO | Option exercise · Series C Convertible Preferred Stock | −1,000,000 | 0 | ||
| 2025-02-26 | Lazar David E. Interim CEO | Option exercise · Series D Convertible Preferred Stock | −1,745,262 | 354,738 | ||
| 2025-02-26 | Ben-Tzvi Avraham Director | Grant or award · Non-Qualified Stock Option (Right to Buy) | +700,000 | 700,000 | ||
| 2025-02-06 | Lazar David E. Interim CEO | Grant or award · Series D Convertible Preferred Stock | +2,100,000 | 2,100,000 | ||
| 2025-01-02 | NATAN DAVID Director | Grant or award | +100,000 | 100,000 | ||
| 2024-01-29 | SCHWARTZ BRIAN Interim Chief Medical Officer | Grant or award | +12,500 | 15,205 | ||
| 2024-01-29 | SCHWARTZ BRIAN Interim Chief Medical Officer | Grant or award · Stock Option (right to buy) | +12,500 | 12,500 | ||
| 2023-12-21 | McBarron Paul See Remarks | Purchase | +1,886 | $3.32 | $6K | 33,378 |
| 2023-12-21 | McBarron Paul See Remarks | Purchase · Warrants (right to buy) | +1,886 | 1,886 | ||
| 2023-12-21 | Rombotis Spiro George President and CEO | Purchase | +6,070 | $3.32 | $20K | 68,658 |
| 2023-12-21 | Rombotis Spiro George President and CEO | Purchase · Warrants (right to buy) | +6,070 | 6,070 | ||
| 2023-06-30 | Rombotis Spiro George President and CEO | Grant or award · Stock Option (right to buy) | +110,000 | 110,000 | ||
| 2023-06-30 | BARKER SAM L Director | Grant or award | +21,219 | 40,415 | ||
| 2023-06-30 | BARKER SAM L Director | Grant or award · Stock Option (right to buy) | +42,438 | 42,438 | ||
| 2023-06-30 | Spiegel Robert J. Director | Grant or award | +21,219 | 39,415 |
Page 3 of 24 · 475 trades